Skip to main content Skip to main navigation menu Skip to site footer
Page Header Logo
  • Current
  • Archives
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Contact
Search
  • Register
  • Login
  1. Home /
  2. Archives /
  3. Vol 2 No 2 (2019)

Published: 2019-06-10

General article

  • Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA Adverse Events Reporting System database.
    Vasiliki Nikolopoulou, Spyridon Siafis, Antonios Milonas, Dimitrios Kouvelas, Georgios Papazisis
    81-93
    • PDF
  • Randomized Controlled Trials: The case of Multiple Sclerosis - Refining the constraints of a treasure, a short outline
    Theodoros S. Constantinidis
    93-103
    • PDF
  • Is there a therapeutic potential for repetitive Transcranial Magnetic Stimulation (rTMS) in the management of cognitive impairment in Multiple Sclerosis?
    Grigorios Nasios, Lambros Messinis
    104-109
    • PDF
  • Does multiple sclerosis cause progressive and widespread cognitive decline?
    Marina Katsari, Dimitrios Kasselimis, Georgios Koutsis, Constantin Potagas
    110-115
    • PDF
  • Is psychosis, at least in part, an immune-related dysmyelination disease?
    Orestis Giotakos
    116-129
    • PDF
Information
  • For Readers
  • For Authors
  • For Librarians

Powered by Interoptics S.A
About this Publishing System